 Entered into Exclusive License Agreement, with 7.5 Million Upfront License Fee and Potential to Receive up to an Additional 194.5 Million, with 3D Medicines for Development and Commercialization of Galinpepimut-S in China; Additional 1 Million Milestone Triggered in February 2021 